Singh H, Lowder KE, Kapner K, et al. Clinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2+ gastroesophageal adenocarcinoma. Nature communications. 2024;15(1):6833. doi:10.1038/s41467-024-51271-3
Publications
Hong L, Hu Z, Sun S, et al. Fast, sensitive detection of protein homologs using deep dense retrieval. Nature biotechnology. 2024. doi:10.1038/s41587-024-02353-6
Asare Y, Georgakis MK. Translating Anti-Inflammatory Strategies for Atherosclerosis: Deep Phenotyping, Next-Generation Drug Targets, and Precision Medicine. Cells. 2024;13(15). doi:10.3390/cells13151306
Asare Y, Georgakis MK. Translating Anti-Inflammatory Strategies for Atherosclerosis: Deep Phenotyping, Next-Generation Drug Targets, and Precision Medicine. Cells. 2024;13(15). doi:10.3390/cells13151306
Asare Y, Georgakis MK. Translating Anti-Inflammatory Strategies for Atherosclerosis: Deep Phenotyping, Next-Generation Drug Targets, and Precision Medicine. Cells. 2024;13(15). doi:10.3390/cells13151306
Ardissino M, Truong B, Slob EAW, et al. Proteome- and Transcriptome-Wide Genetic Analysis Identifies Biological Pathways and Candidate Drug Targets for Preeclampsia. Circulation. Genomic and precision medicine. 2024:e004755. doi:10.1161/CIRCGEN.124.004755
Wang K, Lo CH, Mehta RS, et al. An Empirical Dietary Pattern Associated with the Gut Microbial Features in Relation to Colorectal Cancer Risk. Gastroenterology. 2024. doi:10.1053/j.gastro.2024.07.040
Wang K, Lo CH, Mehta RS, et al. An Empirical Dietary Pattern Associated with the Gut Microbial Features in Relation to Colorectal Cancer Risk. Gastroenterology. 2024. doi:10.1053/j.gastro.2024.07.040
Venkadakrishnan VB, Presser AG, Singh R, et al. Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes. Nature communications. 2024;15(1):6779. doi:10.1038/s41467-024-51156-5
Venkadakrishnan VB, Presser AG, Singh R, et al. Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes. Nature communications. 2024;15(1):6779. doi:10.1038/s41467-024-51156-5